Source-grounded facts extracted from Arcus Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Arcus Biosciences, Inc. shareholders approved The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement at the 2026-06-11 meeting.
“Proposal 3 : The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement: Votes For Votes Against Abstentions Broker Non-Votes 94,920,421 9,337,368 29,741 13,573,227”
Arcus Biosciences, Inc. shareholders approved The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
“Proposal 2 : The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026: Votes For Votes Against Abstentions 112,905,582 4,767,430 187,745”
Arcus Biosciences, Inc. shareholders approved The election of Class II directors to hold office until the 2029 Annual Meeting of Stockholders and until its successor is duly elected and qualified at the 2026-06-11 meeting.
“Proposal 1 : The election of Class II directors to hold office until the 2029 Annual Meeting of Stockholders and until its successor is duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Dietmar Berger, M.D., Ph.D. 85,949,508 18,338,022 13,573,227 David Lacey, M.D. 85,974,583 18,312,947 13,573,227 Nicole Lambert 92,653,341 11,634,189 13,573,227 Johanna Mercier 85,941,754 18,345,776 13,573,227”
Arcus Biosciences, Inc. reported financial results for three months ended March 31, 2026.
“On May 5, 2026 , Arcus Biosciences, Inc. issued a press release announcing its financial results for the three months ended March 31, 2026.”
Arcus Biosciences, Inc. amended First Amendment to the Loan and Security Agreement with Hercules Capital, Inc. valued at $150.0 million (effective 2025-12-18).
“On December 18, 2025 (the “Closing Date”), Arcus Biosciences, Inc. (the “Company”) entered into a First Amendment to the Loan and Security Agreement (the “First Amendment”) with the several banks and other financial institutions or entities party thereto (the “Lenders”), as lenders, and Hercules Capital, Inc. (“Hercules”), as administrative agent and collateral agent.”
Arcus Biosciences, Inc. amended credit facility of $150.0 million term loan commitments with Hercules Capital, Inc. maturing September 1, 2030.
“Agreement, dated as of August 27, 2024, by and among the Company, Hercules and the Lenders (the “Loan Agreement”). The First Amendment amends the terms for the remaining $150.0 million term loan commitments available under the loan facility such that, subject to customary terms and conditions, (a) $25.0 million is available at the Company's sole option through”
Dietmar Berger was appointed as Class II Director at Arcus Biosciences, Inc..
“On February 6, 2025, the Board appointed Dietmar Berger M.D., Ph.D., as a Class II director to fill the vacancy left by Dr. Parsey's resignation.”
Merdad Parsey resigned as Director at Arcus Biosciences, Inc..
“On February 6, 2025, in connection with his departure from Gilead Sciences, Inc. (“Gilead”), Merdad Parsey, M.D., Ph.D., resigned as a member of Arcus Biosciences, Inc.’s (“Arcus”) Board of Directors (the “Board”), effective upon the appointment of Gilead’s new director designee pursuant to the Amended and Restated Investor Rights Agreement dated January 29, 2024 by and between Arcus and Gilead.”
Dimitry Nuyten departed as Chief Medical Officer at Arcus Biosciences, Inc..
“Dimitry Nuyten, M.D., Ph.D. will depart from the Company on January 31, 2025”
Richard Markus was appointed as Chief Medical Officer at Arcus Biosciences, Inc..
“Richard Markus, M.D., Ph.D. has been appointed as the Company’s Chief Medical Officer, effective January 31, 2025”
Arcus Biosciences, Inc. reported the first quarter ended March 31, 2024 results: revenue $145 million.
“to fund operations into 2027. Cash, cash equivalents and marketable securities are expected to be between $870 million and $920 million at the end of 2024. • Revenues were $145 million for the first quarter 2024, compared to $25 million for the same period in 2023. In the first quarter 2024, Arcus recognized $135 million in license and development services”
Arcus Biosciences, Inc. reported financial results for the three months and full year ended December 31, 2023.
“On February 21, 2024, Arcus Biosciences, Inc. issued a press release announcing its financial results for the three months and full year ended December 31, 2023.”
Arcus Biosciences, Inc. amended Amendment No. 3 with Gilead Sciences, Inc. (effective 2024-01-29).
“On January 29, 2024, the Company and Gilead also entered into Amendment No. 3 (“Amendment No. 3”) to the Option, License and Collaboration Agreement, dated May 27, 2020, as amended on November 17, 2021 and May 12, 2023 (as previously amended, the “OLCA”).”
Arcus Biosciences, Inc. entered into Third Amended and Restated Common Stock Purchase Agreement with Gilead Sciences, Inc. (effective 2024-01-29).
“On January 29, 2024, Arcus Biosciences, Inc. (the “Company”) and Gilead Sciences, Inc. (“Gilead”) entered into a Third Amended and Restated Common Stock Purchase Agreement (the “A&R Purchase Agreement”), which amends and restates in its entirety the Second Amended & Restated Common Stock Purchase Agreement dated June 27, 2023 (the “Existing Purchase Agreement”).”
Johanna Mercier was appointed as Class II Director at Arcus Biosciences, Inc..
“the Board appointed Johanna Mercier to the Board as a Class II director”
Ms. Jarrett resigned as Director at Arcus Biosciences, Inc..
“Dr. Jaen and Ms. Jarrett resigned from the Board”
Dr. Jaen resigned as Director at Arcus Biosciences, Inc..
“Dr. Jaen and Ms. Jarrett resigned from the Board”
Arcus Biosciences, Inc. reported financial results for the third quarter ended September 30, 2023.
“On November 7, 2023 , Arcus Biosciences, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2023.”
Arcus Biosciences, Inc. reported financial results for the second quarter ended June 30, 2023.
“Arcus Biosciences, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2023.”
Arcus Biosciences, Inc. amended Second Amended and Restated Common Stock Purchase Agreement with Gilead Sciences, Inc. (effective 2023-06-27).
“On June 27, 2023, Arcus Biosciences, Inc. (“Arcus”) and Gilead Sciences, Inc. (“Gilead”) entered into a Second Amended and Restated Common Stock Purchase Agreement (the “A&R Purchase Agreement”), which amends and restates in its entirety the Amended & Restated Common Stock Purchase Agreement entered into between Arcus and Gilead on January 31, 2021 (the “2021 SPA”).”
Arcus Biosciences, Inc. shareholders approved Advisory approval of named executive officer compensation at the 2023-06-15 meeting.
“Proposal 3 : The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement: Votes For Votes Against Abstentions Broker Non-Votes 56,058,305 2,350,776 50,777 8,655,281”
Arcus Biosciences, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-15 meeting.
“Proposal 2 : The ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023: Votes For Votes Against Abstentions 65,921,166 1,127,268 66,708”
Arcus Biosciences, Inc. shareholders approved Election of directors at the 2023-06-15 meeting.
“Proposal 1 : The election of a director to hold office until the 2026 Annual Meeting of Stockholders and until its successor is duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Dr. David Lacey 40,854,980 17,604,878 8,655,281 Dr. Juan Jaen 43,694,709 14,765,149 8,655,281 Dr. Merdad Parsey 42,680,149 15,779,709 8,655,281 Ms. Nicole Lambert 46,262,513 12,197,345 8,655,281”
Arcus Biosciences, Inc. amended Option, License and Collaboration Agreement Amendment No. 2 with Gilead Sciences, Inc. valued at Upfront payment of $35 million; potential option and milestone payments up to $420 million per progr (effective 2023-05-15).
“On May 15, 2023, Arcus Biosciences, Inc. (“Arcus”) entered into an amendment (“Amendment No. 2”) to its Option, License and Collaboration Agreement with Gilead Sciences, Inc. (“Gilead”) dated May 27, 2020.”
Arcus Biosciences, Inc. reported the first quarter ended March 31, 2023 results: revenue $25 million.
“cash in research and development activities. Cash, cash equivalents and marketable securities on-hand are expected to be sufficient to fund operations into 2026. • Revenues were $25 million for first quarter 2023, compared to $18 million for the same period in 2022. In first quarter 2023, Arcus recognized $17 million in license and development service revenues for”
Robert C. Goeltz II changed role as Principal Accounting Officer at Arcus Biosciences, Inc..
“Concurrent with Mr. Azoy’s appointment as the Company’s Principal Accounting Officer, Robert C. Goeltz II, the Company’s Chief Financial Officer (and in such role was the Company’s Principal Financial Officer), ceased to function as the Company’s Principal Accounting Officer.”
Alexander Azoy was appointed as Principal Accounting Officer at Arcus Biosciences, Inc..
“On March 9, 2023, the Board of Directors (the “Board”) of Arcus Biosciences, Inc. (the “Company”) appointed Alexander Azoy to serve as the Company’s Principal Accounting Officer.”
Arcus Biosciences, Inc. reported financial results for the three months and full year ended December 31, 2022.
“On February 28, 2023, Arcus Biosciences, Inc. issued a press release announcing its financial results for the three months and full year ended December 31, 2022.”
Arcus Biosciences, Inc. reported financial results for the three and nine months ended September 30, 2022.
“On November 2, 2022, Arcus Biosciences, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2022.”
Linda Higgins was appointed as Director at Arcus Biosciences, Inc..
“On August 10, 2021, the Board appointed Linda Higgins, Senior Vice President of Research, External Innovation at Gilead, as a Class III director to fill the vacancy left by Dr. Quigley’s resignation.”
Michael Quigley resigned as Director at Arcus Biosciences, Inc..
“Michael Quigley, Ph.D., resigned as a member of Arcus Biosciences, Inc.’s Board of Directors, effective upon the appointment of Gilead’s new director designee”
Nicole Lambert was appointed as Director at Arcus Biosciences, Inc..
“On August 3, 2021, the Board of Directors of Arcus Biosciences, Inc. appointed Nicole Lambert to the Board as a Class II Director.”
Bill Grossman resigned as Chief Medical Officer at Arcus Biosciences, Inc..
“On July 16, 2021, Bill Grossman, MD, Arcus Biosciences, Inc.’s Chief Medical Officer, resigned from Arcus to become SVP of Oncology Clinical Research at Gilead Sciences, Inc., effective July 26, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.